India Globalization Capital, Inc. announced that the United States Patent and Trademark Office issued a patent (#11,351,152) to the company titled Method and Composition for Treating Seizure Disorders. The patent is assigned to IGC and relates to compositions and methods for treating multiple types of seizure disorders and epilepsy in humans and animals, using a combination of the cannabinoid cannabidiol with other compounds. Subject to further research and study, the combination is intended to reduce side effects caused by hydantoin anticonvulsant drugs such as phenobarbital, by reducing the dosing of anticonvulsant drugs in humans, dogs, and cats.

About 50 million people worldwide are affected by epilepsy (WHO, 2022). Of the approximately 76 million dogs in the U.S. (American Veterinary Medical Association, 2018), about 5% (one in 20 dogs), or about 3.8 million dogs, can suffer from seizures. The company's current plans are to pursue a veterinarian pathway through observational studies and clinical trials aimed towards developing a potential treatment for seizure disorders in dogs and cats.